CINECA IRIS Institutional Research Information System

PELLEGRINI, CAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.666
AS - Asia 3.666
EU - Europa 3.157
SA - Sud America 548
AF - Africa 197
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.253
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.481
IT - Italia 1.498
SG - Singapore 1.262
CN - Cina 957
HK - Hong Kong 570
BR - Brasile 455
VN - Vietnam 306
SE - Svezia 278
DE - Germania 263
FI - Finlandia 173
BG - Bulgaria 162
GB - Regno Unito 160
FR - Francia 148
RU - Federazione Russa 130
JP - Giappone 109
CA - Canada 105
IN - India 105
AT - Austria 80
TR - Turchia 68
CI - Costa d'Avorio 65
NL - Olanda 65
PL - Polonia 52
MX - Messico 46
KR - Corea 37
SN - Senegal 35
AR - Argentina 33
BD - Bangladesh 31
IQ - Iraq 31
UA - Ucraina 31
PK - Pakistan 29
CH - Svizzera 26
IR - Iran 22
ZA - Sudafrica 21
ID - Indonesia 19
UZ - Uzbekistan 17
AU - Australia 16
MA - Marocco 16
PH - Filippine 16
CZ - Repubblica Ceca 15
EC - Ecuador 15
SA - Arabia Saudita 15
BE - Belgio 14
VE - Venezuela 14
CO - Colombia 11
KE - Kenya 11
DZ - Algeria 9
ES - Italia 9
EG - Egitto 8
IE - Irlanda 8
LT - Lituania 8
MY - Malesia 8
NG - Nigeria 8
AE - Emirati Arabi Uniti 7
PT - Portogallo 7
PY - Paraguay 7
TW - Taiwan 7
AZ - Azerbaigian 6
JO - Giordania 6
LB - Libano 6
TN - Tunisia 6
HU - Ungheria 5
JM - Giamaica 5
NO - Norvegia 5
PS - Palestinian Territory 5
UY - Uruguay 5
CL - Cile 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
PA - Panama 4
TT - Trinidad e Tobago 4
AL - Albania 3
AO - Angola 3
DK - Danimarca 3
GD - Grenada 3
GH - Ghana 3
GR - Grecia 3
GT - Guatemala 3
KG - Kirghizistan 3
KZ - Kazakistan 3
MO - Macao, regione amministrativa speciale della Cina 3
NI - Nicaragua 3
RO - Romania 3
TH - Thailandia 3
BH - Bahrain 2
BJ - Benin 2
CR - Costa Rica 2
GE - Georgia 2
IL - Israele 2
LV - Lettonia 2
MK - Macedonia 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
QA - Qatar 2
SV - El Salvador 2
UG - Uganda 2
BB - Barbados 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
Totale 14.237
Salva come PNG Salva come JPEG
Città #
Ashburn 819
Singapore 686
Dallas 639
San Jose 560
Hong Kong 551
Fairfield 481
Santa Clara 412
Woodbridge 329
Chandler 272
Houston 233
Shanghai 209
Seattle 202
Milan 191
Beijing 176
New York 172
Wilmington 170
Cambridge 167
Sofia 160
Serra 156
Pisa 142
Ann Arbor 139
Council Bluffs 139
Los Angeles 135
Boardman 134
Munich 94
Florence 91
Tokyo 88
Rome 81
Princeton 78
Helsinki 68
Ho Chi Minh City 68
Abidjan 65
Lauterbourg 65
Lawrence 59
London 56
Hanoi 54
Vienna 53
Hefei 51
Frankfurt am Main 49
Dong Ket 48
Medford 48
Turku 48
Bremen 46
Lucca 44
Lappeenranta 42
Ottawa 42
Des Moines 40
Redondo Beach 39
Chicago 38
São Paulo 37
Buffalo 35
Dakar 35
Istanbul 33
Montignoso 31
Seoul 31
Naples 29
Warsaw 29
Atlanta 28
Ogden 27
Dearborn 25
Montreal 25
Nanjing 24
Bologna 22
Nuremberg 22
Redwood City 22
Livorno 21
Phoenix 20
Chennai 19
Pistoia 18
Toronto 18
Zurich 18
Rio de Janeiro 17
Tashkent 16
Baltimore 15
Turin 15
Washington 15
Brooklyn 14
Fuzhou 14
San Diego 14
Amsterdam 13
Guangzhou 13
Kent 13
Marseille 13
Poplar 13
Brussels 12
Columbus 12
Manchester 12
Shenzhen 12
Baghdad 11
Brno 11
Da Nang 11
Nairobi 11
Padova 11
Palermo 11
Paris 11
Belo Horizonte 10
Brasília 10
Curitiba 10
Izmir 10
Johannesburg 10
Totale 9.658
Salva come PNG Salva come JPEG
Nome #
Protective effects of Saccharomyces boulardii CNCM I-745 Against Nonsteroidal anti-inflammatory drug-induced intestinal injury 292
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon 273
Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity 272
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 267
Pathophysiology of NSAID-associated intestinal lesions in the rat: Luminal bacteria and mucosal inflammation as targets for prevention 230
Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia 230
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 226
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 226
Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors 216
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? 216
Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition 214
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic 208
Dietary Supplementation with the Probiotic SF68 Reinforces Intestinal Epithelial Barrier in Obese Mice by Improving Butyrate Bioavailability 205
The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity 204
Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation 199
Dietary Supplement, Containing the Dry Extract of Curcumin, Emblica and Cassia, Counteracts Intestinal Inflammation and Enteric Dysmotility Associated with Obesity 196
NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity 194
Enteric protective effects of the combination Bifidobacterium longum and lactoferrin in a rat model of diclofenac-induced intestinal injury. 193
NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? 192
Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity 190
Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity 187
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 186
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 185
The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders 184
Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury 181
Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity 179
Donepezil improves vascular function in a mouse model of Alzheimer's disease 178
Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation 177
Mechanisms underlying the non-anticoagulant effects of apixaban and dabigatran on the integrity of intestinal mucosa: a comparative pre-clinical study. 177
Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy 176
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology 176
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 172
High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse 172
Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats 171
The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications 167
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models 167
The intestinal barrier in disorders of the central nervous system 166
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System? 165
Enteric Glia and Brain Astroglia: Complex Communication in Health and Disease along the Gut-Brain Axis 163
Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship 160
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 157
USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation 156
Adenosine signaling in the tumor microenvironment 154
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 153
Rifaximin Displays a Protective Activity in Experimental Enteropathy Induced by Indomethacin in Rats. 150
Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. 149
Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? 149
Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy 149
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease 147
Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study 145
From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinson's disease 145
Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling 144
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 144
Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis 142
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 142
Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review 137
Enteric glial NLRP3 inflammasome contributes to gut mucosal barrier alterations in a mouse model of diet-induced obesity 136
The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis 135
P2X7 receptor-dependent tuning of gut epithelial responses to infection 134
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation 133
Lactiplantibacillus plantarum HEAL9 attenuates cognitive impairment and progression of Alzheimer's disease and related bowel symptoms in SAMP8 mice by modulating microbiota-gut-inflammasome-brain axis 132
Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients 131
Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rat 127
Development of an adipocyte differentiation protocol using 3T3-L1 cells for the investigation of the browning process: identification of the PPAR-γ agonist rosiglitazone as a browning reference drug 126
Intestinal epithelial barrier and neuromuscular compartment in health and disease 123
Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches 123
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology (npj Parkinson's Disease, (2022), 8, 1, (9), 10.1038/s41531-021-00263-x) 122
Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy 117
Enteric glia at the crossroads between intestinal immune system and epithelial barrier: Implications for parkinson disease 117
Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases 115
Gut-directed therapy in Parkinson’s disease 114
null 114
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 113
Pathological Remodeling of the Gut Barrier as a Prodromal Event of High-Fat Diet-Induced Obesity 111
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications 111
Neuronal regulation of intestinal immune functions in health and disease 110
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence 106
Prolonged treatment with probiotics mitigates intestinal dysfunction and enteric Alzheimer's-related pathology in senescence-accelerated mice 103
null 103
Glomerular hyperfiltration in morbid obesity: Role of the inflammasome signalling 102
Pharmacological modulation of P2X4 in inflammatory bowel diseases: the way towards novel therapeutics? 101
- Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel diseases 101
Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer’s Disease 97
The adenosine system at the crossroads of intestinal inflammation and neoplasia 97
α-Synuclein in Parkinson's Disease: From Bench to Bedside 93
Inflammatory Bowel Diseases: It's Time for the Adenosine System 92
NKG2A and COVID-19: another brick in the wall 87
Adenosine signaling as target in cardiovascular pharmacology 85
LRRK2 is reduced in Parkinson’s disease gut 79
Neuromuscular Function Abnormalities 78
Editorial: IBD Management—Novel Targets and Therapeutic Perspectives 78
The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice 76
Velusetrag rescues GI dysfunction, gut inflammation and dysbiosis in a mouse model of Parkinson's disease 73
LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines 63
Gastrointestinal dysmotility in rodent models of Parkinson’s disease 57
Are LRRK2 mysteries lurking in the gut? 56
Editorial: Reviews in neuropharmacology 2023: microbiota gut-brain axis, therapeutic insights for neurodegenerative diseases 46
How leaky is the gut in Parkinson’s disease? 43
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome 31
Special Issue “Drugs in Inflammatory Bowel Diseases” 31
Totale 14.617
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.548
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.548
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021124 0 0 0 0 0 0 0 0 0 0 0 124
2021/2022751 27 16 18 25 146 113 41 36 62 41 49 177
2022/20231.195 120 151 89 93 114 138 24 106 220 41 78 21
2023/20241.326 78 105 162 98 184 218 49 80 79 49 111 113
2024/20253.443 56 114 72 192 266 413 328 142 382 403 371 704
2025/20264.963 296 480 705 436 472 334 714 259 333 564 180 190
Totale 14.647